Incidence and Predictors of Long Term Cardiotoxicity in Antracycline Based Chemotherapy in Breast Cancer Patients

Novos Biomarcadores Cardiovasculares em Pacientes com Câncer de Mama Submetidas a Quimioterapia à Base de Doxorrubicina

“…No entanto, não foram observadas diferenças em indivíduos que desenvolveram cardiotoxicidade secundária às antraciclinas em comparação com indivíduos sem cardiotoxicidade. 42 Estudos experimentais e clínicos substanciais são necessários para esclarecer o comportamento da FABP3 neste contexto. A correlação positiva entre FABP3 e FABP4 com o IMC já era esperada, uma vez que esses marcadores estão diretamente associados ao tecido adiposo e ao metabolismo lipídico.…”

“…However, no differences were observed in those individuals who developed cardiotoxicity secondary to anthracyclines compared to individuals without onset cardiotoxicity. 42 Substantial experimental and clinical studies are necessary to clarify FABP3 behavior in this context. The positive correlation between FABP3 and FABP4 with BMI was already expected since these markers are directly associated with adipose tissue and lipid metabolism.…”

Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer

“…Surprisingly, chemotherapy was associated with worse mortality for patients younger than 50 years who had pT1a tumors. Reasons for this observation are unclear, although it may be in part because of worse chemotherapy toxic effects outweighing its benefits for pT1a tumors 4 and younger cohorts receiving chemotherapy with more aggressive tumor biology. 5 Pertinent variables, such as performance status, tumor recurrence, and toxicity, were unavailable in the National Cancer Database, resulting in unmeasured confounding despite matching.…”